Antimalarial drugs are key tools for the control and elimination of malaria. Recent decreases
in the global malaria burden are likely due, in part, to the deployment of artemisinin-based …

Malaria remains a major cause of morbidity and mortality in the tropics, with Plasmodium
falciparum responsible for the majority of the disease burden and P. vivax being the …

Background Efficient allocation of resources to intervene against malaria requires a detailed
understanding of the contemporary spatial distribution of malaria risk. It is exactly 40 y since …

Background The World Health Organization recommends uncomplicated P. falciparum
malaria is treated using Artemisinin‐based Combination Therapy (ACT). This review aims to …

Malaria remains one of the leading health problems of the developing world, and Uganda
bears a particularly large burden from the disease. Our understanding is limited by a lack of …

Objectives To compare the efficacy and safety of artemether-lumefantrine (AL) and
dihydroartemisinin-piperaquine (DP) for treating uncomplicated falciparum malaria in …

Background. Artemisinin-based combination therapy (ACT) reduces the potential for malaria
transmission, compared with non-ACTs. It is unclear whether this effect differs between …

Polymorphisms in the Plasmodium falciparum pfmdr1 gene were assayed in pretreatment
samples and in samples from patients reinfected following therapy with artemether …

Background Uganda recently adopted artemether-lumefantrine (AL) as the recommended
first-line treatment for uncomplicated malaria. However, AL has several limitations, including …

Malaria, particularly that one caused by Plasmodium falciparum, remains a serious health
problem in Africa, South America, and many parts of Asia where it afflicts about 500 million …